In partnership with
Thanks to Starlink, I’m writing to you today from high up in a tree, all alone in a deer stand.
As I sit here in the remote, snowy mountains of West Virginia, my trigger finger's half-frozen, my nose is running like a busted faucet, and I’ve yet to scope a worthy buck.
But no one gives a darn about my hypothermia, my inability to properly type, or the lack of big game thus far…
Because we’re here to talk about IPOs.
So, before my digits go completely numb, let’s get into it.
Next week, there's a sharp entry into the diagnostic imaging services arena, where providers are rolling out advanced scans and reads for everything from routine checkups to complex cancer diagnostics.
This outfit’s gearing up to offer 25 million shares priced between $17 and $20 each, potentially pulling in $500 million and slapping a $1.9 billion valuation on the whole operation.
Yes, they’ll debut as a small cap!
They’re listing on Nasdaq, backed by solid players like Barclays, J.P. Morgan, Deutsche and Jefferies.
It’s the kind of move that screams confidence in a sector that’s firing on all cylinders, blending high-tech gear with on-the-ground service delivery to meet exploding demand.
And, because I like its prospects, it’s an IPO I’ll be giving full details on to IPO Stream Premium members.
Shoppers are adding to cart for the holidays
Over the next year, Roku predicts that 100% of the streaming audience will see ads. For growth marketers in 2026, CTV will remain an important “safe space” as AI creates widespread disruption in the search and social channels. Plus, easier access to self-serve CTV ad buying tools and targeting options will lead to a surge in locally-targeted streaming campaigns.
Read our guide to find out why growth marketers should make sure CTV is part of their 2026 media mix.
You see, diagnostic imaging isn’t just about those MRI machines humming in hospital basements anymore. No, it’s the backbone of modern medicine, powering faster, more accurate diagnoses that save lives and cut costs.
We’re talking X-rays, ultrasounds, CTs, and MRIs that spot issues early, from heart blockages to sneaky tumors.
This company’s homing in on outpatient and freestanding centers, where flexibility meets efficiency, serving up quick turnaround reads via a network of radiologists armed with AI tools for sharper insights.
And get this: the industry’s been crushing it lately. Back in 2024, the US diagnostic imaging services market alone clocked in at around $140 billion, with a healthy 10% uptick driven by post-pandemic catch-up care and an aging population piling into clinics.
Fast-forward to next year, and we’re looking at possible $160 billion or so US market. A 14%+ increase.
Why the boom?
Let’s go global. Chronic diseases like diabetes and cardiovascular woes are spiking. Over 500 million adults worldwide grappling with diabetes alone, each needing regular scans to track complications.
Add in elective procedures rebounding hard after COVID delays, and you’ve got utilization rates jumping 15% in key markets like the U.S. and Europe.
Hospitals and outpatient spots are investing big too, with $20 billion funneled into new imaging suites and mobile units last year.
Tech’s the secret sauce. AI algorithms are slashing false positives by up to 30% while hybrid modalities like PET-CT fuse data for pinpoint accuracy.
Waiting times are down, patient satisfaction’s up, and reimbursements from insurers are flowing steadier under value-based care models.
It’s not hype; it’s measurable. U.S. Medicare data shows imaging volumes up 8% year-over-year, with private payers following suit.
But hold onto your seat: By 2034, projections peg the US market alone hitting $276 billion (a near doubling from 2024), with some forecasts stretching toward $300 billion and beyond if AI adoption accelerates.
What’s fueling it? Precision medicine is the next big wave. Personalized treatments demand granular imaging data, especially in oncology where targeted therapies rely on real-time tumor mapping.
We may expect 20% growth in advanced modalities like 7-tesla MRIs and low-dose CTs for lung screening, backed by guidelines pushing preventive scans for at-risk groups.
The EVOLVING regulatory landscape helps too. FDA greenlights for AI-enhanced diagnostics are piling up, cutting approval times by half and opening doors for smaller providers.
Emerging markets in Asia and Latin America may chip in 25% of the gains, as infrastructure builds out with $10 billion in foreign investments.
Even headwinds like labor shortages? They’re easing with teleradiology platforms connecting experts across time zones, boosting throughput without burnout.
Look, next week’s debut slots right into that momentum, showcasing how nimble operators are scaling networks to capture share in a fragmented field.
With margins improving, industry averages at 15% EBITDA, and M&A heating up (over $5 billion in deals this year), it’s a sector ripe for steady climbers.
If you’re eyeing ways to navigate these waters, tracking the right signals can turn trends into real edges. As someone deep in the analytics game, I’ve seen how early positioning pays off.
Now, as I rub my hands together to warm my now numb fingers, and continue waiting for a trophy buck to find his way into my sight…
I want you to know that I fully believe this IPO could be a real trophy.
-Tim
